The EFFERVESCENT trial is designed to evaluate the effects of a specific ARB, called
valsartan, on atherosclerosis. The investigators want to know if treatment with valsartan
will increase the blood levels of markers responsible for repair of the vessel wall, reduce
oxidation and inflammation, improve the function of the blood vessels, and arrest or slow
down the progression of atherosclerosis over time.